Public References

Since its creation, MEDSHARING provides the public sector with solutions tailored to its specific characteristics.

EOL© is used in many studies and registries in various therapeutic areas.

To date more than 40 studies have been conducted for the public sector for the recruitment of 300 to over 5000 patients, in oncology, digestive surgery, cardiology and neurology.

MEDSHARING is present in UHs and research units in France, Belgium and Germany.

We can, upon request, organise an exchange with our public customers to enable you to assess EOL© with your colleagues.


Some significant studies:

• National Network for the Study of Predictors and Prevention of Sudden Unexpected Deaths in drug-resistant partial epilepsy.

• Randomised trial comparing the internal jugular and femoral catheterisation in terms of iatrogenic, nosocomial complications and quality of dialysis in intensive care in the ERA.

• Comparison of pelvic lymphadenectomy with isolated sample from the sentinel node in early cervical cancer: randomised multicentre study with assessment of medical-economic impacts.

• Your project
• An all-inclusive package budget
• A well-tried methodology
• Designing your study
• A site dedicated to training

• Our e-CRF solutions
• EOL, e-crf 100% internet
• Handling your study
• Data collection
• Monitoring and validation
• Exporting to your tools

• Our randomization solutions
• IPhone/IPad Randomization
• IWRS Randomization
• Randomization algorithm
• Allocation of treatments
• Vocal server IVRS

• references
• Public References
• Laboratory references
• Associations references
• Customer testimonials
• Our achievements

• security and quality
• Your data secure
• High qualifications
• Unfailing availability
• Our healthcare host

• The e-crf advantages
• Quality data
• Optimal communication
• Traceability and confidentiality
• Optimized costs

EOL, the e-CRF solution

An e-CRF solution for the complete on-line management of clinical studies available on the Internet (tests, cohorts, health monitoring)

Our news

Quote request

+33 (0)1 48 75 39 14
by e-mail